Molbio Diagnostics, an innovative point-of-care diagnostics company, has been awarded the KOCHON Prize 2024 by the Stop TB Partnership.This recognition honours Molbio’s work in ensuring access to the latest tools, innovations, andapproaches for people affected by Tuberculosis (TB) and in advancing progress toward theUNHLM targets. With this award, Molbio becomes the first private company globally—andonly the third Indian entity after the Indian Council of Medical Research (ICMR) and Dr. L.SChauhan—to receive this distinction.About the Kochon PrizeAwarded annually by the Stop TB Partnership, the Kochon Prize recognizes individuals andorganizations that have made significant contributions to combating tuberculosis. Established bythe Kochon Foundation in memory of its late chairman, Chong-Kun Lee, the award carries aprize of USD 65,000 and a medal, making it the world’s largest award specifically dedicated to TB. The 2024 theme recognizes people, teams, or organizations that, day by day, demonstrate how tosuccessfully ensure access for people with TB to the latest tools, innovations, and innovative approaches that are leading to impact on the UN High Level Meeting targets.